NAFLD Clinical Care Pathway
Non-alcoholic fatty liver disease (NAFLD) is a new condition that has become the most common chronic liver disease in the world and a main cause of liver cirrhosis, liver failure and liver cancer. Obesity and diabetes, conditions that are very common among Veterans are the main risk factors for NAFLD. Therefore, the bu
| Condition(s) | NAFLD, MASLD |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Non-alcoholic fatty liver disease (NAFLD) is a new condition that has become the most common chronic liver disease in the world and a main cause of liver cirrhosis, liver failure and liver cancer. Obesity and diabetes, conditions that are very common among Veterans are the main risk factors for NAFLD. Therefore, the burden of NAFLD and its complications among Veterans is substantial. However, most VA patients with NAFLD are undiagnosed and untreated, and their care is not consistent with practice guidelines. The NAFLD Clinical Care Pathway (NCCP) intervention seeks to close this major gap in the care of Veterans by automatically identifying patients at risk of NAFLD, calculating their risk scores of having severe NAFLD, and educating the primary care providers on the diagnosis and treatmen |
| Who can participate | Inclusion Criteria: Patient Aligned Care Teams (PACT) at the Michael E. DeBakey VA Medical Center Exclusion Criteria: * The investigators will exclude PACTs with unstable leadership (i.e., pending departure, vacancy) at time of randomization. * PACTs participating in the focus groups in Aim 1 will be excluded in Aim 2 to avoid cross contamination. * PACTs meeting the following criteria will be excluded from randomization in Aim 2: * PACTs who do not treat NAFLD, * PACTs not located at the main hospital, * PACTs with less than 100 visits within 3 months. |
| Ages | 18 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | VA Office of Research and Development |
| Locations | Houston, Texas, United States |
| Start date | 2024-02-02 |
| NCT ID | NCT06671886 |
| Official listing | https://clinicaltrials.gov/study/NCT06671886 |